Last reviewed · How we verify
0.01% hypochlorous acid
At a glance
| Generic name | 0.01% hypochlorous acid |
|---|---|
| Also known as | 0.01%HOCI |
| Sponsor | Eye & ENT Hospital of Fudan University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine (PHASE4)
- Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (PHASE3)
- 0.01% Hypochlorous Acid in the Treatment of Blepharitis (NA)
- Viral Conjunctivitis Treatment Study (NA)
- Ocular Comfort and Inflammation in Lid Hygiene Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.01% hypochlorous acid CI brief — competitive landscape report
- 0.01% hypochlorous acid updates RSS · CI watch RSS
- Eye & ENT Hospital of Fudan University portfolio CI